Automated QPatch-HT System: Providing a Higher-throughput hERG Safety Assay with Better Consistency

New York – May 31st, 2019 – Acroscell, as a division of Creative Bioarray, offering an innovative, time-efficient, cost-effective and comprehensive range of preclinical R&D services. With strong scientific support, Acroscell currently specialized in but not limited to cardiovascular & neural system physiological/pathophysiological mechanisms. Recently, it announced the release of its automated QPatch-HT system which can provide a higher-throughput hERG safety assay with better consistency.

Drug-induced cardiovascular complications limit the use of many successful clinical therapies such as anticancer therapies. Cardiovascular complications caused by most medications include significant cardiac dysfunction and some negative effects such as high blood pressure, ischemia and arrhythmias. Much effort and investment have been made in the development of new drugs to determine adverse cardiovascular responses and minimize patient risk. About one-third of compounds in preclinical development show a certain degree of heart disease risk.

Acroscell has a team of experts who have years of experience in ion channel safety testing and cardiotoxicity assessment, providing in vitro electrophysiological services (such as hERG safety) and in vivo (eg ECG QT) analysis.

The Kv11.1 channel is a potassium ion channel (also known as the hERG channel) encoded by the human ether-related (hERG) gene and plays a key role in the repolarization of cardiac action potentials. Inhibition of hERG function leads to prolonged ventricular action potential duration and is the most common mechanism for QT interval prolongation. Therefore, assessing the effects of compounds on hERG activity early in drug discovery can greatly reduce the risk of doing a lot of effort in cardiotoxic drugs and preventing them from entering the market. The ICH S7B guidelines regulate in vitro I Kr assays (e.g., hERG safety assays) and in vitro QT assays for identifying and assessing the potential of test compounds to delay ventricular repolarization.

Acroscell performs hERG safety testing according to the ICH S7B guidelines to assess composite cardiovascular safety and support drug development.

The hERG inhibition test (screening or GLP compatible, pre-IND test) provides extraordinary sensitivity, much greater than full organ analysis or whole animal analysis. Of course, proper research design and data interpretation can reduce the risk of false positives due to this huge sensitivity.

‘Acroscell utilizes the most advanced automated QPatch-HT system to deliver higher throughput hERG safety analysis at a lower cost.’ said Hannah Cole, the marketing director of Creative Bioarray, she also claimed, ‘For small amounts of compounds or compounds identified using QPatch, we can also perform routine whole-cell patch clamp assays to obtain detailed mechanical information. Our GLP level hERG security analysis provides high quality data for registration purposes.’

About Acroscell

As a global leading provider of quality services in research and development focusing on cardiac & neuronal safety profiling and translational assays, Acroscell can offer a comprehensive cell bank with a variety of specialized and unique stable cell lines expression to support a variety of in vitro research and in vivo pharmacology study, thereby promoting the development of drug screening and profiling.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road Shirley
City: Long Island City
State: New York
Country: United States